nach oben

Erschienen in:

23.01.2018 | Original Paper

Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats

verfasst von: Bianca Facchim Gonçalves, Silvana Gisele Pegorin de Campos, Wagner José Fávaro, Joyce Zalotti Brandt, Cristiane Figueiredo Pinho, Luis Antônio Justulin, Sebastião Roberto Taboga, Wellerson Rodrigo Scarano

Erschienen in: Discover Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Use of drug combinations that target different pathways involved in the development and progression of prostate cancer (PCa) has emerged as an alternative to overcome the resistance caused by drug monotherapies. The antiandrogen abiraterone acetate and the PI3K/Akt inhibitor NVP-BEZ235 (BEZ235) may be suitable options for the prevention of drug resistance and the inhibition of PCa progression. The aim of the present study was to evaluate whether abiraterone acetate and BEZ235 achieve superior therapeutic effects to either drug administered as monotherapy, in the early stages of PCa in an androgen-dependent system. Our study showed that each drug might impair tumor growth by reducing proliferation and increasing cell death when administered as monotherapy. However, tumor growth continued to progress with each drug monotherapy and some important side effects were related to BEZ. Conversely, when used in combination, the drugs impaired the inflammatory response, decreased hyperplastic lesions, and blocked tumor progression from premalignant to a malignant stage. Our data showed that the strategy to block the androgenic and PI3K/AKT/mTOR pathway is an effective therapeutic option and should be investigated including distinct PI3K pathway inhibitors.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):134CrossRef

Ferlay J, Shin HR, Bray F (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, Lyon

Jain S, Saxena S, Kumar A (2014) Epidemiology of prostate cancer in India. Meta Gene 2:596–605CrossRefPubMedPubMedCentral

Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339(15):1036–1042. https://doi.org/10.1056/NEJM199810083391504 CrossRefPubMed

Ferraldeschi R, Sharifi N, Auchus RJ, Attard G (2013) Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 19(13):3353–3359. https://doi.org/10.1158/1078-0432.CCR-12-0931 CrossRefPubMedPubMedCentral

Bracarda S, de CO, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de BF, Bartsch G (2005) Cancer of the prostate. Crit Rev Oncol Hematol 56(3):379–396. https://doi.org/10.1016/j.critrevonc.2005.03.010 CrossRefPubMed

Reid AH, Attard G, Barrie E, de Bono JS (2008) CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 5(11):610–620. https://doi.org/10.1038/ncpuro1237 CrossRefPubMed

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 17:575–586CrossRef

Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6(2):76–85. https://doi.org/10.1038/ncpuro1296 CrossRefPubMedPubMedCentral

10.

Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW (2014) Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget 5(19):9335–9348. https://doi.org/10.18632/oncotarget.2429 CrossRefPubMedPubMedCentral

11.

Wadia R, Petrylak DP (2014) New developments in the treatment of castration resistant prostate cancer. Asian J Androl 16(4):555–560. https://doi.org/10.4103/1008-682X.127824 CrossRefPubMedPubMedCentral

12.

Goldberg T, Berrios-Colon E (2013) Abiraterone (Zytiga), a novel agent for the management of castration-resistant prostate cancer. P T 38(1):23–26PubMedPubMedCentral

13.

Grossebrummel H, Peter T, Mandelkow R, Weiss M, Muzzio D, Zimmermann U et al (2016) Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int J Oncol 48(2):793–800. https://doi.org/10.3892/ijo.2015.3274 CrossRefPubMed

14.

Wang Y, Yu Q, He X, Romigh T, Altemus J, Eng C (2014) Activation of AR sensitizes breast carcinomas to NVP-BEZ235’s therapeutic effect mediated by PTEN and KLLN upregulation. Mol Cancer Ther 13(2):517–527. https://doi.org/10.1158/1535-7163.MCT-13-0655 CrossRefPubMed

15.

Serra V, Markman B, Scaltriti M et al (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022CrossRefPubMed

16.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D et al (2008) Identifcation and characterization of NVP-BEZ234, a new orally available dual PI3K/mTOR inhibitor with potent in vivo antitumor activity. Mol Can Ther 7(7):1851–1863. https://doi.org/10.1158/1535-7163.MCT-08-0017 CrossRef

17.

Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315:485–497. https://doi.org/10.1016/j.yexcr.2008.11.007 CrossRefPubMed

18.

Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3(1):44–51. https://doi.org/10.1158/2159-8290.CD-12-0262 CrossRefPubMed

19.

Marques RB, Aghai A, de Ridder CM, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM (2015) High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur Urol 67(6):1177–1185. https://doi.org/10.1016/j.eururo.2014.08.053 CrossRefPubMed

20.

Sawyer C, Sturge J, Bennett DC, O’Hare MJ, Allen WE, Bain J et al (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63(7):1667–1675PubMed

21.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST (2015) Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol Cancer Ther 14(1):48–58. https://doi.org/10.1158/1535-7163.MCT-14-0406 CrossRefPubMed

22.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M (2014) Dual phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol 191(1):227–234. https://doi.org/10.1016/j.juro.2013.07.101 CrossRefPubMed

23.

Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ (2017) A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer. Oncologist 22(5):503–e43. https://doi.org/10.1634/theoncologist.2016-0432 CrossRefPubMedPubMedCentral

24.

Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE (2004) A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 10(15):5282–5292. https://doi.org/10.1158/1078-0432.CCR-03-0828 CrossRefPubMed

25.

Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R (2008) Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68(7):2366–2374. https://doi.org/10.1158/0008-5472.CAN-07-5783 CrossRefPubMed

26.

Kaarbo M, Mikkelsen OL, Malerod L, Qu S, Lobert VH, Akgul G et al (2010) PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 32(1-2):11–27. https://doi.org/10.3233/CLO-2009-0487 PubMedPubMedCentral

27.

Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM (2012) Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol 41(2):425–432. https://doi.org/10.3892/ijo.2012.1487 CrossRefPubMedPubMedCentral

28.

Edlind MP, Hsieh AC (2014) PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 16(3):378–386. https://doi.org/10.4103/1008-682X.122876 CrossRefPubMedPubMedCentral

29.

Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6):792–804. https://doi.org/10.1016/j.ccr.2011.05.006 CrossRefPubMedPubMedCentral

30.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A (2013) Synergistic targeting of PI3K/AKT-pathway and androgen-receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 12(11):2342–2355. https://doi.org/10.1158/1535-7163.MCT-13-0032 CrossRefPubMed

31.

Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, Cheung CS, Ho K, Chan AT (2014) Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett 343(1):24–32. https://doi.org/10.1016/j.canlet.2013.09.007 CrossRefPubMed

32.

Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira SM, Wymann MP (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7(4):601–613. https://doi.org/10.1158/1541-7786.MCR-08-0366 CrossRefPubMed

33.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V (2011) Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res 17:5322–5332CrossRefPubMed

34.

Bosland MC, Tuomari DL, Elwell MR, Shirai T, Ward JM, McConnel RF (1998) Proliferative lesions of the prostate and other accessory sex glands in male rats. Guides for Toxicologic Pathology, Washington, DC

35.

Gonçalves BF, Campos SGP, Zanetoni C, Scarano WR, Falleiros Júnior LR, Amorin RL, Góes RM, Taboga SR (2013) A new proposed rodent model of chemically induced prostate carcinogenesis: distinct time-course prostate cancer progression in the dorsolateral and ventral lobes. Prostate 73(11):1202–1213. https://doi.org/10.1002/pros.22669 CrossRefPubMed

36.

Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64(6):2270–2305. https://doi.org/10.1158/0008-5472.CAN-03-0946 CrossRefPubMed

37.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17(18):5913–5925. https://doi.org/10.1158/1078-0432.CCR-11-0728 CrossRefPubMedPubMedCentral

38.

Huggins C, Hodges CV (1941) Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297

39.

Bentel JM, Pickering MA, Pollard M, Clements JA, Tilley WD (1999) Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines. In Vitro Cell Dev Biol Anim 35(10):655–662. https://doi.org/10.1007/s11626-999-0106-5 CrossRefPubMed

40.

Liao Z, Boileau TW, Erdaman JW Jr, Clinton SK (2005) Increased phospho-AKT is associated with loss of the androgen receptor during the progression of N-methyl-N-nitrosourea-induced prostate carcinogenesis in rats. Prostate 64(2):186–199. https://doi.org/10.1002/pros.20224 CrossRefPubMed

41.

Zhao Y, Tindall DJ, Huang H (2014) Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci 10(6):614–619. https://doi.org/10.7150/ijbs.8389 CrossRefPubMedPubMedCentral

42.

Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857–868. https://doi.org/10.1016/S0092-8674(00)80595-4 CrossRefPubMed

43.

Tzivion G, Dobson M, Ramakrishnan G (2011) FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813(11):1938–1945. https://doi.org/10.1016/j.bbamcr.2011.06.002 CrossRefPubMed

44.

Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H et al (2007) Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282(10):7329–7338. https://doi.org/10.1074/jbc.M610447200 CrossRefPubMed

45.

Schmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N (2007) Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 120(6):1284–1292. https://doi.org/10.1002/ijc.22359 CrossRefPubMed

46.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489−501CrossRefPubMed

47.

Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVPBEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 106(52):22299–22304. https://doi.org/10.1073/pnas.0905152106 CrossRefPubMedPubMedCentral

48.

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Gonzalez BM, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K (2017) Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur J Cancer 76:36–44CrossRefPubMed

49.

Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK, Cheng JQ (2004) Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279(7):5405–5412. https://doi.org/10.1074/jbc.M312044200 CrossRefPubMed

50.

Zhang X, Tang N, Hadden TJ, Rishi AK (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813(11):1978–1986. https://doi.org/10.1016/j.bbamcr.2011.03.010 CrossRefPubMed

51.

Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61(5):1862–1868PubMed

52.

Yang E, Jockel J, Zha J, Korsmeyer S (1994) Bad, a new bcl-2 family member, heterodimerizes with bcl-2 and bcl-XL in vivo and promotes cell death. Blood 84(suppl 1):373

53.

Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116(2):205–219. https://doi.org/10.1016/S0092-8674(04)00046-7 CrossRefPubMed

54.

Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B et al (2001) Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur Cytokine Netw 12(4):654–663PubMed

55.

Smith AJ, Karpova Y, D'Agostino R Jr, Willingham M, Kulik G (2009) Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One 13:e6224CrossRef

56.

Netland IA, Førde HE, Sleire L, Leiss L, Rahman MA, Skeie BS, Gjerde CH, Enger PØ, Goplen D (2016) Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. BMC Cancer 16:657. https://doi.org/10.1186/s12885-016-2712-4 CrossRefPubMedPubMedCentral

57.

Cao P, Maira SM, Garcia-Echeverria C, Hedley DW (2009) Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100(8):1267–1276. https://doi.org/10.1038/sj.bjc.6604995 CrossRefPubMedPubMedCentral

58.

Diaz-Gonzalez R, Kuhlmann FM, Galan-Rodriguez C, Madeira da Silva L, Saldivia M, Karver CE et al (2011) The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS Negl Trop Dis 5(8):e1297. https://doi.org/10.1371/journal.pntd.0001297 CrossRefPubMedPubMedCentral

59.

Smith GC, Ong WK, Rewcastle GW, Kendall JD, Han W, Shepherd PR (2012) Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J 442(1):161–169. https://doi.org/10.1042/BJ20111913 CrossRefPubMedPubMedCentral

60.

Farram E, Nelson DS (1980) Mouse mast cells as anti-tumor effector cells. Cell Immunol 55(2):294–301. https://doi.org/10.1016/0008-8749(80)90162-8 CrossRefPubMed

61.

Henderson WR, Chi EY, Jong EC, Klebanoff SJ (1981) Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system. J Exp Med 153(3):520–533. https://doi.org/10.1084/jem.153.3.520 CrossRefPubMed

62.

Benyon RC, Imai T, Abe T, Befus D (1991) Mast cell heterogeneity: protein composition, biosynthesis and mRNA characterization. Int Arch Allergy Appl Immunol 94(1–4):218–219. https://doi.org/10.1159/000235364 CrossRefPubMed

63.

Taverna G, Giusti G, Seveso M et al (2013) Mast cells as a potential prognostic marker in prostate cancer. Dis Markers 35(6):711–720CrossRefPubMedPubMedCentral

64.

Nakai Y, Nelson WG, DeMarzo AM (2007) The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 67(3):1378–1384. https://doi.org/10.1158/0008-5472.CAN-06-1336 CrossRefPubMed

65.

Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A (2007) Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 97(7):952–956. https://doi.org/10.1038/sj.bjc.6603962 CrossRefPubMedPubMedCentral

66.

Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland M, Vega K, Kallajoki M, Santti R, Pylkkänen L (2008) Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. Prostate 68(7):728–739. https://doi.org/10.1002/pros.20719 CrossRefPubMed

67.

De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):56–69CrossRef

68.

Stock D, Groome PA, Siemens DR (2008) Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin N Am 35(1):117–130. https://doi.org/10.1016/j.ucl.2007.09.006 CrossRef

69.

Lucia MS, Torkko KC (2004) Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171(2 Pt 2):S30–S34 discussion S35CrossRefPubMed

70.

Culig Z (2014) Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol 2(3):231–238PubMedPubMedCentral

71.

Taniguchi K, Karin M (2014) IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26(1):54–74. https://doi.org/10.1016/j.smim.2014.01.001 CrossRefPubMed

72.

Torrealba N, Rodríguez-Berriguete G, Fraile B, Olmedilla G, Martínez-Onsurbe P, Guil-Cid M, Paniagua R, Royuela M (2017) Expression of several cytokines in prostate cancer: correlation with clinical variables of patients. Relationship with biochemical progression of the malignance. Cytokine 89:105–115. https://doi.org/10.1016/j.cyto.2016.08.008 CrossRefPubMed

73.

Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90(12):2312–2316. https://doi.org/10.1038/sj.bjc.6601814 CrossRefPubMedPubMedCentral

74.

Culig Z, Puhr M (2012) Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 360(1-2):52–58. https://doi.org/10.1016/j.mce.2011.05.033 CrossRefPubMedPubMedCentral

75.

Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367(2):103–107. https://doi.org/10.1016/j.canlet.2015.07.009 CrossRefPubMed

76.

Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC (2000) HER-2/neu promotes androgen-independent survival growth of prostate cancer cells through the Akt pathway. Cancer Res 60(24):6841–6845PubMed

77.

Thorpe LM, Yuzugullu H, Zhao JJ et al (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15:7–24CrossRefPubMedPubMedCentral

Titel: Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats
verfasst von: Bianca Facchim Gonçalves
Silvana Gisele Pegorin de Campos
Wagner José Fávaro
Joyce Zalotti Brandt
Cristiane Figueiredo Pinho
Luis Antônio Justulin
Sebastião Roberto Taboga
Wellerson Rodrigo Scarano
Publikationsdatum: 23.01.2018
Verlag: Springer US
Erschienen in: Discover Oncology / Ausgabe 3/2018
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-018-0323-z

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor?

Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome

Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application

Thyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer

Thyroid Hormone in the Clinic and Breast Cancer

Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie